A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter phase II trial designed to determine efficacy and safety
of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with
advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).